Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: Population based case-control study

BMJ (Online)

Volumn 340, Issue 7741, 2010, Pages 303-

  Boger Megiddo, Inbal ^a   Heckbert, Susan R ^a   Weiss, Noel S ^b   McKnight, Barbara ^b   Furberg, Curt D ^c   Wiggins, Kerri L ^a   Delaney, Joseph A C ^b   Siscovick, David S ^a   Larson, Eric B ^d   Lemaitre, Rozenn N ^a   Smith, Nicholas L ^a   Rice, Kenneth M ^b   Glazer, Nicole L ^a   Psaty, Bruce M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; DIURETIC AGENT; FELODIPINE; LISINOPRIL; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; EXPOSURE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; STROKE; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE;

EID: 76149110511     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c103     Document Type: Article

References (29)

1. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
2. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a networkmetaanalysis. JAMA 2003;289:2534-44.
3. Chobanian AV,BakrisGL, BlackHR, CushmanWC,Green LA, Izzo JL Jr, et al for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.
4. National Collaborating Centre for Chronic Conditions. Hypertension: management in adults in primary care-pharmacological update. Royal College of Physicians, 2006.
5. Beard K, Bulpitt C, Mascie-Taylor H, O'Malley K, Sever P, Webb S. Management of elderly patients with sustained hypertension. BMJ 1992;304:412-6.
6. Neal B, MacMahon S, Chapman N for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
7. The National Heart, Lung, and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials. Major clinical trials of hypertension: what should be done next? Hypertension 2005;46:1-6.
8. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
9. Kleinbaum D, Klein M. Logistic regression: a self-learning text. 2nd ed. Springer, 2002.
10. Horton NJ, Kleinman KP. Much ado about nothing: a comparison of missing datamethods and software to fit incomplete data regression models. Am Stat 2007;61:79-90.
11. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:1927-36.
12. Lechat P, PackerM, Chalon S, CucheratM, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a metaanalysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
13. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Longterm ACE-inhibitor therapy in patients with heart failure or leftventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitormyocardial infarction collaborative group. Lancet 2000;355:1575-81.
14. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.
15. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33.
16. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al for the INVEST investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamiltrandolapril study (INVEST)-a randomized controlled trial. JAMA 2003;290:2805-16.
17. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al for the LIFE Study Group. Cardiovascularmorbidity andmortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
18. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascularmorbidity andmortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 1999;353:611-6.
19. Hansson L, LindholmLH, EkbomT, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity-the Swedish trial in old patients with hypertension-2 study. Lancet 1999;354:1751-6.
20. Dahlof B, Sever PS, Poulter NR,Wedel H, Beevers DG, CaulfieldM, et al for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
21. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
22. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? JAMA 2006;295:1704-6.
23. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L,Dumitrascu D, et al for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98.
24. Jamerson K,WeberMA,BakrisGL,Dahlof B, Pitt B, Shi V, et al for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
25. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension: lesson XVI. How to choose the correct drug treatment for each hypertensive patient using a plasma renin-based method with volume-vasoconstriction analysis. Am J Hypertens 2001;14:491-503.
26. DuckworthW, Abraira C,Moritz T, Reda D, Emanuele N, Reaven PD, et al for the VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl JMed 2009;360:129-39.
27. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al for the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
28. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-75.
29. National Institutes of Health. Systolic Blood Pressure Intervention Trial (SPRINT) Clinical Center Networks. 2008. www.fbo.gov/index? s=opportunity&mode=form&id=375cd800f9e5d76c94d4ee f6e73b01b8&tab= core&-cview=1.